The tools ideate on Boston Scientific’s Farapulse PFA system, which contributed towards a 172% uptick in the company’s Q4 ...

Boston Scientific announced won CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software.

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Revolutionary new software for the treatment of atrial fibrillation (AFib) has been rolled out for Irish patients in Dublin’s ...

Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Adjusted EPS for Q4 was $0.70, surpassing the high-end guidance of $0.66. The FARAPULSE system saw significant adoption, reaching over $1 billion in global revenue in 2024. The WATCHMAN franchise ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Why it matters: The first year of rolling out Farapulse in the US has been a smashing success, and we think Boston has made the most of its opportunity to upset what had been the long-standing ...

ALBANY, N.Y. ( NEWS10) — A new device is transforming the type of treatment some heart patients with atrial fibrillation receive. Doctors say it’s safer to use and improving outcomes for those who ...